Interaction Between Meningococcal Serogroup B Vaccine (Bexsero™) and Routine Infant Vaccines on the Risk of Occurrence and Recurrence of Adverse Events Following Immunization.

Trial Profile

Interaction Between Meningococcal Serogroup B Vaccine (Bexsero™) and Routine Infant Vaccines on the Risk of Occurrence and Recurrence of Adverse Events Following Immunization.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Meningococcal-vaccine-group-B-OMV-GlaxoSmithKline/Finlay (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); MMR-varicella zoster virus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Meningococcal group B infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top